Polymorphisms in DNA repair genes, including doublestrand break (DSB) repair genes, are postulated to confer increased cancer risk. A variant of the XRCC3 gene, which is involved in DSB repair, has been associated with increased risk of malignant skin melanoma and bladder cancer. We tested the hypothesis that this variant, Thr241Met, may aect cancer risk by disrupting a critical function of XRCC3, i.e., promoting homology-directed repair (HDR) of chromosomal DSBs. Using a quantitative¯uorescence assay, we ®nd that the variant XRCC3 protein is functionally active for HDR, complementing the HDR defects of an XRCC3 mutant cell line as well as the wild-type protein. We also examined cells expressing this variant for sensitivity to the interstrand cross-linking agent, mitomycin C (MMC), as HDR mutant cell lines, including the XRCC3 mutant, have been found to be hypersensitive to this DNA damaging agent. Cells expressing the variant protein were found to be no more sensitive than cells expressing the wild-type protein. These results suggest that the increased cancer risk associated with this variant may not be due to an intrinsic HDR defect.
XRCC3, a paralog of the strand-exchange protein RAD51 (Liu et al., 1998) , functions in homologydirected repair (HDR) of double-strand breaks (DSBs) in mammalian cells (Pierce et al., 1999) . XRCC3-de®cient irs1SF cells are severly impaired in their ability to undergo HDR (Pierce et al., 1999; Brenneman et al., 2000) and also to form DNA damageinduced RAD51 nuclear foci (Bishop et al., 1998) . Moreover, irs1SF cells are extremely sensitive to DNA cross-linking agents and have a high incidence of spontanteous and mutagen-induced chromosomal aberrations (Cui et al., 1999; Liu et al., 1998; Tebbs et al., 1995) . Defects in chromosome segregation have also been observed in these cells (Grin et al., 2000) . Several lines of evidence indicate that XRCC3 interacts with both RAD51C, another RAD51 paralog, and possibly RAD51 itself (Kurumizaka et al., 2001; Liu et al., 1998; Masson et al., 2001; Schild et al., 2000) , and recent experiments demonstrate that the XRCC3-RAD51C complex binds DNA, with a higher anity for single-stranded DNA than for double-stranded DNA (Kurumizaka et al., 2001; Masson et al., 2001) .
Emerging evidence suggests that DSB repair genes, like other genes involved in DNA repair, act as genomic caretakers, by preventing cells from accumulating the genetic alterations that promote tumorigenesis (Pierce et al., 2001b) . Therefore, inheritance of repair genes with reduced DNA repair activity is predicted to lead to an increased cancer risk. Population studies have been undertaken to identify XRCC3 variants and to determine their association with the development of cancer (Butkiewicz et al., 2001; David-Beabes et al., 2001; Matullo et al., 2001; Winsey et al., 2000) . The XRCC3 variant allele Thr241Met has been identi®ed in healthy individuals with a frequency ranging from 0.231 to 0.382 (David-Beabes et al., 2001; Matullo et al., 2001; Shen et al., 1998; Winsey et al., 2000) . Two epidemiological studies reported no association of the Thr241Met variant with the development of lung cancer (Butkiewicz et al., 2001; David-Beabes et al., 2001) ; however, a statistically sign®cant increase in variant allele frequency was reported in melanoma skin cancer and bladder cancer groups (allele frequencies 0.43 and 0.48, respectively) (Matullo et al., 2001; Winsey et al., 2000) .
To test whether the variant XRCC3 protein could restore the ability of XRCC3-de®cient irs1SF cells to repair DSBs by homologous recombination, wild-type and variant cDNAs ( Figure 1a ) were cloned into a pCAGGS expression vector. The cDNAs dier by a C to T transition, which results in the distinct NlaIII restriction patterns for the expression vectors ( Figure  1b) . To assess the ability of each of these proteins to promote HDR, we used a quantiative in vivo DSB repair assay previously developed for the irs1SF cell line (Pierce et al., 1999) . The assay utilizes the DR-GFP reporter substrate, which quanti®es HDR of an ISceI endonuclease-generated chromosomal DSB by cellular green¯uorescence (Figure 2a ). This substrate is composed of two dierent mutated green¯uores-cence protein (GFP) genes: SceGFP, mutated to contain the I-SceI site so as undergo a DSB when ISceI is expressed in vivo, and iGFP, a 5' and 3' truncated (internal) fragment that can correct the mutation in the SceGFP gene.
Wild-type AA8 hamster cells and the derivative XRCC3-de®cient irs1SF cell line were previously constructed to contain the DR-GFP substrate at single copy in their genome, creating the DRaa-40 and DRirs-10 cell lines, respectively (Pierce et al., 1999) . Using the cell lines we have analysed the requirement for expression of both I-SceI and XRCC3 for ecient HDR. In the absence of I-SceI expression, GFP positive cells are rare in both cell lines (Figure 2b ). With I-SceI expression, homologous recombination is induced in the wild-type DRaa-40 cells, such that 0.70% of the cell population is GFP positive in this experiment. This strong induction of HDR is not seen in the XRCC3-de®cient cells unless an XRCC3 expression vector is co-transfected with the I-SceI expression vector, in which case similar levels of HDR are found in the wild-type and complemented mutant cells. Thus, HDR is dependent upon expression of both I-SceI and XRCC3, consistent with previous results (Pierce et al., 1999) .
We next compared the activities of the wild-type and variant XRCC3 proteins to complement the HDR defect of the irs1SF cells. Using a wide range of concentrations of each XRCC3 expression plasmid, we found no dierence in the ability of the wild-type and variant XRCC3 expression vectors to complement the HDR defect of the XRCC3-de®cient cells (Figure 2b ± d) . Even at the lowest vector concentrations, similar levels of complementation are observed for transfection of either the wild-type or variant XRCC3 expression vector (e.g., for 50 ng, 0.15+0.02% for wild-type versus 0.13+0.04% for variant, Figure 2d ). We also coexpressed I-SceI with wild-type or variant XRCC3 in the wild-type cell line (DRaa-40) to test whether any dominant-negative eect on HDR would occur, since individuals carrying a single variant allele appear to have a higher cancer risk (Matullo et al., 2001; Winsey et al., 2000) . Our results indicate no dominant negative eect when the variant allele is expressed (Figure 2e ). Furthermore, we compared the eect of the wild-type and variant XRCC3 proteins on DSB repair pathways in addition to HDR, utilizing a PCR assay that quanti®es total homologous and nonhomologous repair events leading to loss of the genomic I-SceI site in the DRirs-10 cells (Pierce et al., 2001a) . In these experiments, we found similar levels of I-SceI site loss whether the wild-type or variant XRCC3 protein is expressed (data not shown). Thus, by examining repair of an induced DSB we ®nd that there is no detectable dierence between the wild-type and variant XRCC3 proteins in the ability to complement the HDR defect of XRCC3-de®cient cells.
Apart from repair of a single DSB, XRCC3 also plays a role in the repair of more global DNA damage arising from carcinogen treatment, and it is conceivable that repair of these other types of damage are not being repaired as eciently by the variant protein.
Previous studies have shown that XRCC3 promotes the repair of DNA damage arising from the interstrand cross-linking agent mitomycin C (MMC) (Tebbs et al., 1995) . We compared the ability of the wild-type and variant XRCC3 to correct the hypersensitivity of the irs1SF cells to this DNA damaging agent. Our results indicate that wild-type AA8 cells, as expected, are not aected by 0.2 mM MMC (surviving fraction of 1.2+0.1), whereas the irs1SF cell line showed a 4100-fold hypersensitivity (surviving fraction of 0.008+0.004) (Figure 3 ). Transient transfection of the expression vector for either the wild-type or variant XRCC3 protein just prior to MMC exposure partially corrected the irs1SF MMC hypersensitivity to a similar extent (surviving fraction of 0.18+0.005 for wild-type protein versus 0.17+0.001 for the variant protein). Therefore, we are not able to detect a signi®cant dierence between the wild-type and variant proteins in their ability to correct the hypersensitivity of the irs1SF cells to this DNA damaging agent.
Thus, our results indicate that the variant XRCC3 protein is able to complement the HDR defect in XRCC3-de®cient irs1SF cells to a similar extent as the wild-type protein, whether this is measured directly using a homologous recombination reporter substrate or indirectly by the ability of cells to repair DNA damage arising from a cross-linking agent. The ®nding that this variant protein has HDR activity is perhaps not surprising considering that individuals homozygous for the variant allele are viable. Although an Xrcc3 The polymorphism results in distinct NlaIII restriction enzyme patterns in which a 171 bp fragment is cleaved to 108 and 63-bp fragments. Wild-type and variant Thr241Met XRCC3 cDNAs were cloned into a pCAGGS expression vector (Miyazaki et al., 1989) by amplifying the XRCC3 cDNA from pXR3-10 (a gift from L Thompson, Livermore), utilizing the high ®delity Vent DNA polymerase (New England Biolabs). Wild-type XRCC3, ampli®ed utilizing the sense primer-A (5'-CCGGAATTCGCCAC-CATGGATTTGGA-TCTA-3') and anti-sense primer-D (5'-CCGGAATTCTCAGTGGGACTGGGT-3'), was cloned into pCAGGS as an EcoRI fragment. Variant XRCC3 was created by amplifying two independent fragments. Fragment 1 was ampli®ed utilizing the sense primer-A and anti-sense primer-B (5 '-GGCACTGCTCAGCTCACGCAGCATGGCCCCCAGGG-ACTG-3'). Fragment 2 was ampli®ed utilizing the sense primer-C (5'-CTGCGTGAGCTGAGCAGTGCC-3') and anti-sense primer-D. Ampli®ed fragments were digested with BlpI, ligated together, and then cloned into pCAGGS as an EcoRI fragment. PCR ®delity was ver®ed by DNA sequencing. Both proteins are expressed from a hCMV enhancer/chicken b-actin promoter in the pCAGGS vector, as is I-SceI in the expression vector pCBASce (see Pierce et al., 2001a) Oncogene Variant XRCC3 implicated in cancer is functional in HDR FD Araujo et al DRaa-40 and DRirs-10 cell lines have been previously described (Pierce et al., 1999) . Electroporations were performed with logphase cells in 650 ml phosphate buered saline using a Bio-RAD Gene Pulser II set to 250 V, 1000 mF in a 0.4 cm cuvette. In each case, 50 mg of the I-SceI vector were electroporated in each case, except in the untransfected panels in (b); the amount of the XRCC3 expression vectors was variable (b, 10 mg; c and d, as indicated; e, 20 mg) mouse disruption has not as yet been reported, disruption of three of the ®ve Rad51 paralogs leads to embryonic lethality (see Pierce et al., 2001b) suggesting that a null mutation in Xrcc3 would also lead to developmental defects. Nevertheless, partial loss of function XRCC3 alleles may be compatible with viability; yet in our assay, in which the only variable is the single amino acid change in the XRCC3 allele, no detectable dierence in HDR activity was observed between the variant and wild-type alleles.
The Thr241Met variant XRCC3 has been, on one hand, associated with the development of melanoma skin cancer (Winsey et al., 2000) , and bladder cancer (Matullo et al., 2001) , while on the other hand, no association has been observed with the development of lung cancer including adenocarcinoma, squamous plus small cell carcinoma, and other cell types (Butkiewicz et al., 2001; David-Beabes et al., 2001) . Several explanations are possible for the seeming discrepancies between these epidemiological studies and by the lack of an observed DNA repair defect. First, diverse tissue types are known to be dierentially impacted for tumor progression as a result of DNA repair defects, as for example colon and skin, from mismatch repair and nucleotide excision repair defects, respectively (Vogelstein and Kinzler, 1998) . Thus, the observed cancer association may be due to skin and bladder speci®c factors not present in lung. However, a cell-type restriction in tumor formation is not usually associated with a similar restriction in the manifestation of the DNA repair defect. For example, for DSB repair defects, i.e., as a result of BRCA1 and BRCA2 mutation, tumors occur primarily in breast and ovary, but the HDR repair defect is present in other cell types as well (see Moynahan et al., 2001) . Nevertheless, we cannot formally rule out a cell-type speci®c defect in DSB repair as a result of the XRCC3 polymorphism, which is not recapitulated in our hamster cell assay. Nor can we rule out genetic interactions between the variant XRCC3 and polymorphic alleles of other DNA repair genes that may lead to an HDR defect, or even an extremely mild HDR defect, that would not be detectable in our assays.
Other possible explanations relate to the case-control studies. XRCC3 could be in linkage disequilibrium with another gene responsible for the cancer association. Additionally, it is notable that allele frequencies between dierent control groups in the case ± control studies showed a large range for the variant allele (range 0.30 to 0.38) (Butkiewicz et al., 2001; DavidBeabes et al., 2001; Matullo et al., 2001; Shen et al., 1998) . The dierence in allele frequency within heathly subjects is even more pronounced when comparing dierent ethnic populations, such as African ± Americans (0.231) with Caucasians (0.382) (David-Beabes et al., 2001) . This variation points to the need for wellmatched control groups in order to rule out population variation as the underlying reason for an apparent cancer risk.
Finally, it is possible that XRCC3 participates in other cellular pathways not assayed here. Thus far, separation-of-function alleles have not been identi®ed for XRCC3 in which HDR is intact yet some other cellular phenotype is defective. It has, however, been presumed that chromosome instability and other repair phenotypes of the XRCC3-de®cient cells are due to the HDR defect, as the same phenotypes are found in other HDR mutants (Pierce et al., 2001b) .
In summary, we found that, within the limits of detection of our assays, the common and variant XRCC3 alleles are functionally equivalent for HDR, suggesting that the reported cancer risk associated with this variant XRCC3 is not caused by an overt HDR defect. , except in the untransfected controls, followed by a 24-h incubation period to allow transient expression. Electroporations were performed as described above in the legend to Figure 2 . Survival was measured for exponentially growing cells exposed to MMC (0.2 mM) for 1 h at 378C. Single-cell suspensions were prepared by trypsin treatment, and cells were plated at various concentrations into 10 cm dishes. After a 7-day period, the cells were ®xed in methanol and stained in 5% Giemsa. Surviving fractions were determined as the number of colonies on treated plates divided by the number of colonies on untreated plates
